Landscapes / Companies

EMD Serono Research & Development Institute, Inc. not checked

FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
2 approved
2 in Phase 3
Next date
Avelumab, Phase 3 trial completes
Drugs
10
in active trials · 26 in all
Trials
13 active
66 since 2021

Drugs10

DrugHow it worksPartnerStageNext dateDetails
Programmed death ligand-1 blocker
Approved 24 Nov 2026soonPhase 3 trial completes
Kinase inhibitor
Merck KGaA, Darmstadt, Germany
Approved —
Artificial immunoglobulin
Phase 3 23 Dec 2027Phase 1/2 trial completes
—
Phase 3 12 Aug 2028Phase 2 trial completes
—
Phase 2 —
—
Phase 1 22 Feb 2027Phase 1 trial completes
—
Phase 1 22 Feb 2027Phase 1 trial completes
—
Phase 1 16 Apr 2027Phase 1 trial completes
—
Phase 1 28 Sep 2028Phase 1 trial completes
—
Phase 1 23 Feb 2029Phase 1 trial completes

About

No active trial
16 other drugs
SEC filings
None: it does not file with the US SEC
Sources
ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021

Follow EMD Serono Research & Development Institute, Inc.

Following is part of Solo: you see every change to EMD Serono Research & Development Institute, Inc. the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in